| 1-DP2-EB035891-01 |
A Novel Class of Synthetic Receptors to Empower the Age of mRNA Therapies |
Xiaojing Gao |
Stanford University |
| 1-R01-EB031936-01 |
Semi-synthetic, magneto-photonic circuit for non-invasive control of cellular function |
Ute Hochgeschwender |
Central Michigan University |
| 1-R01-EB035016-01 |
Engineering human-derived programmable RNA effectors to retune gene expression |
Bryan Dickinson |
University of Chicago |
| 1-R21-EB031306-01 |
Selectively Replicating Trojan Virus Vectors as Programmable CRISPR-Based Antiviral Therapies |
Michael Phelps |
Washington State University |
| 1-R21-EB033121-01A1 |
Glia Exclusive Gene Therapy |
Or Shemesh |
University of Pittsburgh at Pittsburgh |
| 1-R21-EB033459-01A1 |
A Novel Vector Platform to Actualize T Cell Modification In Vivo |
David Curiel |
Washington University |
| 1-R21-EB033963-01A1 |
Mitigating the Immunogenicity of Engineered Aav Gene Delivery Vectors by Biomaterial-Driven Immunosuppression |
Shaoyi Jiang |
Cornell University |
| 1-R21-EB035261-01 |
Programmable 'all-in-one' RNA as a molecular scaffold for targeted combinatorial innate immune activation |
Connie Wu |
University of Michigan at Ann Arbor |
| 5-R01-EB027895-04 |
Accelerating phage evolution and tools via synthetic biology and machine learning |
Sam Nugen |
Cornell University |
| 5-R01-EB028320-04 |
Programmable Synthetic Organelles Built from Disordered Proteins for Cellular Engineering |
Matthew Good |
University of Pennsylvania |
